Damora Therapeutics (DMRA) vs Kailera Therapeutics (KLRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kailera Therapeutics is the larger company by market cap ($1.30 billion vs $1.27 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | KLRA |
|---|---|---|
| Share price | $20.56 | $10.00 |
| Market cap | $1.27B | $1.30B |
| 1-day change | +1.58% | -5.03% |
| YTD return | -10.65% | — |
| 1-year return | +93.05% | — |
| 5-year return | -75.95% | — |
| EPS (TTM) | $-0.25 | $-4.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $28.23 |
| 52-week low | $4.95 | $9.76 |
| Distance from 52-week high | -46.35% | -64.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +128.06% | +324.00% |
| Average volume | 531.94K | 861.01K |
| Shares outstanding | 61.74M | 129.64M |
| Employees | 7 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Kailera Therapeutics
KLRA stock →Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
DMRA vs KLRA FAQ
Which is bigger, Damora Therapeutics or Kailera Therapeutics?
Kailera Therapeutics (KLRA) is larger, with a market capitalization of $1.30B compared with $1.27B for Damora Therapeutics (DMRA).
Are Damora Therapeutics and Kailera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.